209 related articles for article (PubMed ID: 17197005)
1. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; Charles BG
Aust Vet J; 2004 Dec; 82(12):769-72. PubMed ID: 15648940
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos (Cacatua galerita).
Filippich LJ; Charles BG; Sutton RH; Bucher AM
Aust Vet J; 2004 Jun; 82(6):366-9. PubMed ID: 15267096
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
8. Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients.
Morris RG; Reece PA; Dale BM; Green RM; Kotasek D; Saccoia NC; Sage RE
Ther Drug Monit; 1989; 11(4):380-3. PubMed ID: 2741185
[TBL] [Abstract][Full Text] [Related]
9. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion.
Filippich LJ; Bucher AM; Charles BG
Aust Vet J; 2000 Jun; 78(6):406-11. PubMed ID: 10920780
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes.
Tonetti M; Astroff AB; Satterfield W; De Flora A; Benatti U; DeLoach JR
Am J Vet Res; 1991 Oct; 52(10):1630-5. PubMed ID: 1767983
[TBL] [Abstract][Full Text] [Related]
11. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.
Webster LK; Cosson EJ; Stokes KH; Millward MJ
Br J Cancer; 1996 Feb; 73(4):522-4. PubMed ID: 8595168
[TBL] [Abstract][Full Text] [Related]
12. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).
Callies S; de Alwis DP; Wright JG; Sandler A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2003 Feb; 51(2):107-18. PubMed ID: 12647011
[TBL] [Abstract][Full Text] [Related]
13. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
[TBL] [Abstract][Full Text] [Related]
14. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
Averbach A; Stuart OA; Chang D; Sugarbaker PH
Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of doxorubicinol in dogs.
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
J Vet Pharmacol Ther; 2006 Oct; 29(5):433-5. PubMed ID: 16958789
[No Abstract] [Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample.
Leca FR; Marchiset-Leca D; Galeani A; Noble A; Catalin J
Anticancer Drugs; 1998 Jul; 9(6):503-9. PubMed ID: 9877237
[TBL] [Abstract][Full Text] [Related]
18. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
Abou El Hassan MA; Kedde MA; Zwiers UT; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Apr; 51(4):306-10. PubMed ID: 12721758
[TBL] [Abstract][Full Text] [Related]
19. Quantification of pegylated liposomal doxorubicin and doxorubicinol in rat plasma by liquid chromatography/electrospray tandem mass spectroscopy: Application to preclinical pharmacokinetic studies.
Liu Y; Yang Y; Liu X; Jiang T
Talanta; 2008 Jan; 74(4):887-95. PubMed ID: 18371724
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
